Johnson & Johnson (JNJ) vs. Pfizer (PFE): Key Differences
JNJ vs PFE: The Numbers
Side by side on the figures we publish for both companies. Not a ranking and not a recommendation — the same metrics, read off the same source, on the same day.
| Metric | JNJJohnson & Johnson | PFEPfizer Inc. |
|---|---|---|
| MoonshotScore | 89 | 66 |
| Price | $266.59 | $27.65 |
| Change (1D) | +0.09% | -0.47% |
| Market cap | $642.5B | $157.6B |
| P/E ratio | 29.2 | 36.5 |
A dash means we hold no published figure for that company — not a zero. Full analysis: JNJ · PFE.
Stock Comparison: JNJ vs. PFE
“MoonshotScore rates a US-listed stock 0 to 100 — higher means stronger numbers. Most carry an older nine-factor score; the rest use five sector-relative pillars, re-ranked daily — common stocks and ADRs only. Funds, ETFs, warrants, units, SPACs, preferreds, and notes carry none. It is built for education and deeper due diligence, not financial advice.”
Questions worth resolving before acting on the screen
What are the primary business segments of Johnson & Johnson (JNJ)?
JNJ operates across pharmaceuticals, medical devices, and consumer health products, offering diversification within the healthcare sector.
What is Pfizer's (PFE) main area of focus?
Pfizer primarily concentrates on the development, manufacturing, and marketing of pharmaceutical products and vaccines.
How do JNJ and PFE compare in terms of market capitalization?
Market capitalization reflects the total market value of a company's outstanding shares and can indicate company size and market influence.
What factors should investors consider when comparing pharmaceutical stocks like JNJ and PFE?
Investors should consider pipeline products, patent expirations, regulatory approvals, and overall financial health when evaluating pharmaceutical stocks.